CoChat

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer

Open access
Sanchez-Vega, Francisco, Hechtman, Jaclyn F., Castel, Pau, Ku, Geoffrey Y., Tuvy, Yaelle, Won, Helen, Fong, Christopher J., Bouvier, Nancy, Nanjangud, Gouri J., Soong, Joanne, Vakiani, Efsevia, Schattner, Mark, Kelsen, David P., Lefkowitz, Robert A., Brown, Karen, Lacouture, Mario E., Capanu, Marinela, Mattar, Marissa, Qeriqi, Besnik, Cecchi, Fabiola, Tian, Yuan, Hembrough, Todd, Nagy, Rebecca J., Lanman, Richard B., Larson, Steven M., Pandit-Taskar, Neeta, Schöder, Heiko, Iacobuzio-Donahue, Christine A., Ilson, David H., Weber, Wolfgang A., Berger, Michael F., de Stanchina, Elisa, Taylor, Barry S., Lewis, Jason S., Solit, David B., Carrasquillo, Jorge A., Scaltriti, Maurizio, Schultz, Nikolaus, Janjigian, Yelena Y. · 2019 · Cancer Discovery
Cited by 150

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an irreversible pan-HER kinase inhibitor, in trastuzumab-resistant EG cancer. We analyzed pretreatment tumor biopsies and, in select cases, performed comprehensive characterization of postmortem metastatic specimens following acquisition of drug resistance. Afatinib response was associated with coamplification of EGFR and ERBB2. Heterogeneous 89Zr-trastuzumab PET uptake was associated with genomic heterogeneity and mixed clinical response to afatinib. Resistance to afatinib was associated with selection for tumor cells lacking EGFR amplification or with acquisition of MET amplification, which could be detected in plasma cell-free DNA. The combination of afatinib and a MET inhibitor induced complete tumor regression in ERBB2 and MET coamplified patient-derived xenograft models established from a metastatic lesion progressing on afatinib. Collectively, differential intrapatient and interpatient expression of HER2, EGFR, and MET may determine clinical response to HER kinase inhibitors in ERBB2-amplified EG cancer. Significance: Analysis of patients with ERBB2-amplified, trastuzumab-resistant EG cancer who were treated with the HER kinase inhibitor afatinib revealed that sensitivity and resistance to therapy were associated with EGFR/ERBB2 coamplification and MET amplification, respectively. HER2-directed PET imaging and cell-free DNA sequencing could help guide strategies to overcome the emergence of resistant clones. See related commentary by Klempner and Catenacci, p. 166. This article is highlighted in the In This Issue feature, p. 151

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-0598

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 150

Metadata

Authors
Sanchez-Vega, F., Hechtman, J. F., Castel, P., Ku, G. Y., Tuvy, Y., Won, H., Fong, C. J., Bouvier, N., Nanjangud, G. J., Soong, J., Vakiani, E., Schattner, M., Kelsen, D. P., Lefkowitz, R. A., Brown, K., Lacouture, M. E., Capanu, M., Mattar, M., Qeriqi, B., Cecchi, F., Tian, Y., Hembrough, T., Nagy, R. J., Lanman, R. B., Larson, S. M., Pandit-Taskar, N., Schöder, H., Iacobuzio-Donahue, C. A., Ilson, D. H., Weber, W. A., Berger, M. F., de Stanchina, E., Taylor, B. S., Lewis, J. S., Solit, D. B., Carrasquillo, J. A., Scaltriti, M., Schultz, N., & Janjigian, Y. Y.
Venue
Cancer Discovery
Published
2019-02-01
Volume
9
Issue
2
Pages
199-209
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2901467300
Cited by
150
References
12
FWCI
5.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.